UPCC 11522 A Multicenter Phase II Study of Pomalidomide Monotherapy in Kaposi Sarcoma
Enrolling By Invitation
99 years or below
All
Phase
N/A
15 participants needed
1 Location
Brief description of study
This phase II trial studies the effect of pomalidomide in treating patients with Kaposi sarcoma. Pomalidomide is a cancer fighting drug that stops the growth of blood vessels, stimulates the immune system, and may kill cancer cells.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Kaposi Sarcoma
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 851611
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
